ATTO — Q2 2026 Financial Report Analysis

Overview

Attovia Therapeutics, a San Carlos, California drug developer that listed on Nasdaq in August 2026, lost $20.7 million in the second quarter of 2026, 43% more than the $14.4 million it lost a year earlier. The wider loss came almost entirely from research and development (R&D) spending, which rose 39% to $18.9 million as the company paid outside labs and manufacturers to finish the first human trial of its lead drug, ATTO-1310, and to prepare two more candidates for the clinic.

Attovia is a clinical-stage biotech: it has drug candidates being tested in people but nothing approved for sale, so it has no product revenue and funds itself by selling shares. This 10-Q covers the three months to June 30, 2026, which ended before the IPO closed on August 6, 2026. The balance sheet below therefore does not include the roughly $305.4 million of net IPO proceeds, and the share count and per-share loss are pre-IPO figures.

At a glance

• $115.1 million of cash and investments at June 30, down from $152.3 million at the end of 2025. Adding the ~$305.4 million of net IPO proceeds gives roughly $420 million, which management says funds operations "into 2030".
• $18.9 million of quarterly R&D, up 39% year on year and 13% on the first quarter ($16.7 million). Spending is accelerating, as it should for a company moving a drug toward larger trials.
• $0.45 million of revenue, the company's first in 2026, for research work done for EndPath RadioTherapeutics, a company that licensed part of Attovia's antibody technology. It is not drug sales and is too small to matter for the investment case.

The numbers

Figures in USD millions except per share. The company had no revenue in the second quarter of 2025, so a percentage change is not meaningful (n/m).

For the first half of 2026, the net loss was $39.3 million against $29.6 million a year earlier, and R&D was $35.7 million against $25.4 million (+40%).

Where the money went

The filing breaks R&D into outside and in-house costs, which shows the increase is trial and manufacturing work rather than overhead:

Management attributes the $4.8 million rise in outside services to "CRO and CMO development activities related to ATTO-1310, ATTO-2306, ATTO-3712 and ATTO-1091". A CRO (contract research organization) runs clinical trials for a drug company, and a CMO (contract manufacturing organization) makes the drug supply. About three-quarters of R&D now goes to these outside providers, which is typical for a small biotech and means spending can be scaled up or down fairly quickly.

Interest income fell 44% to $1.1 million because the company had less cash invested than a year earlier, when it had just raised $142 million in private funding rounds (Series B and C). That will reverse next quarter, since the IPO nearly quadrupled the cash pile.

The pipeline, in plain terms

All three named drugs come from Attovia's ATTOBODY platform, an antibody-design technology it licenses from Alamar Biosciences.

• ATTO-1310 blocks IL-31, a signalling protein that drives itching. It finished a Phase 1 trial: the first stage of human testing, which checks safety and dosing in a small group. Part 1a in healthy volunteers showed, per the company, "favorable tolerability, rapid and sustained suppression of IL-31, and low immunogenicity" (low immunogenicity means the body did not readily form antibodies against the drug). Part 1b, in patients with chronic itch and with eczema (atopic dermatitis, AD) where itch dominates, is fully dosed. The company calls the preliminary results "clinical proof of concept", saying a single dose was followed by rapid itch relief in both groups. Complete Phase 1b data are expected in Q4 2026. Two Phase 2 trials, the mid-stage studies that test whether a drug works in a larger patient group, are planned for the first half of 2027: one in chronic pruritus of unknown origin (CPUO, persistent itch with no identified cause) and one in high-itch AD. China's drug regulator also cleared a Phase 1b trial in itch caused by two liver diseases (PBC and PSC).
• ATTO-2306 targets both IL-31 and IL-13 (an eczema driver) in a single molecule. It is in IND-enabling studies, the animal and manufacturing work required before the FDA will allow human testing. Phase 1 is expected in the first half of 2027.
• ATTO-1091 targets three inflammation pathways at once (TL1A, IL-23 and integrin α4β7) for inflammatory bowel disease, also with Phase 1 expected in the first half of 2027.

Caution on the ATTO-1310 data: the "proof of concept" is the company's own description of preliminary, small-trial results that have not yet been published in full. The complete Phase 1b dataset in Q4 2026 is the first chance to judge the size and duration of the effect against a placebo group.

What the headline numbers hide

• The per-share loss will drop sharply next quarter, and that will not be an improvement. The $4.88 loss per share is spread over only about 4.2 million weighted common shares, because before the IPO most of the company was owned through preferred stock. At the IPO that preferred converted into 21.5 million common shares and 19.55 million new shares were sold; 45.7 million shares were outstanding on August 31. The same dollar loss spread over roughly ten times as many shares will look far smaller per share. Track the dollar loss and cash burn, not loss per share.
• The "stockholders' deficit" of $145.5 million is an accounting presentation, not insolvency. The $258.2 million of preferred stock sat outside shareholders' equity on the June 30 balance sheet. It converted to common stock at the IPO, so the deficit disappears from the next balance sheet.
• Cash burn was slightly flattered by paying suppliers later. Operating cash outflow in the first half ($34.9 million) was $4.4 million less than the net loss ($39.3 million). About $2.3 million of that gap is non-cash costs such as stock-based pay ($1.4 million) and lease charges. The rest is working-capital timing: the largest single item was a $3.2 million rise in accounts payable (bills received but not yet paid, which grew from $3.6 million to $6.0 million on the balance sheet), partly offset by paying down accrued expenses and lease liabilities. That benefit from paying suppliers later will reverse when those bills are settled.
• One prior-year item makes general and administrative (G&A) costs look better than they are. First-half G&A fell 10% to $6.5 million, but the 2025 half included a $0.4 million write-off of costs from an earlier, abandoned offering attempt. In the second quarter alone, without that item, G&A rose 9%, and management expects it to "increase substantially" with the costs of being a public company.
• The revenue is incidental. The $0.45 million comes from research services under the EndPath license for radioligand drugs (radioactive cancer drugs), a field outside Attovia's own focus. A further $0.6 million is held as a customer deposit and could be recognized later. Treat it as a small offset to costs, not a business line.
• No going-concern warning. The filing contains no "substantial doubt" language; management states that cash plus IPO proceeds will last at least 12 months from the filing date, and its own plan runs into 2030.

Did last time's read hold up? This is our first report on Attovia; it listed on Nasdaq in August 2026 and this 10-Q is its first quarterly filing. Against its own stated plans, Phase 1 dosing of ATTO-1310 was completed in the first quarter of 2026 as the filing describes, and the Phase 1 start for ATTO-2306 and ATTO-1091 is now given as the first half of 2027.

Takeaway: The quarter's loss matters less than the cash position after the IPO. About $420 million (June cash plus IPO proceeds) against a current operating burn of roughly $35 million per half-year gives Attovia room to run two Phase 2 trials for ATTO-1310 and put two more drugs into human testing without raising money again soon. The "into 2030" runway still assumes spending roughly doubles, so the investment case now depends on whether the full Phase 1b data in Q4 2026 support those larger trials.

Outlook

Management's guidance: complete ATTO-1310 Phase 1b data in Q4 2026; Phase 2 trials in CPUO and high-itch AD starting in the first half of 2027; Phase 1 starts for ATTO-2306 and ATTO-1091 in the first half of 2027; a development-candidate nomination for an early program (ATTO-006) by year-end 2026; cash runway "into 2030". Management also says R&D will "increase substantially for the foreseeable future".

Our read: the runway figure implies average spending of roughly $120 million a year through 2029, against an annualized operating cash burn of about $70 million in the first half of 2026. That gap matches the plan: two global Phase 2 trials plus two Phase 1 programs starting in 2027 would cost far more than one finishing Phase 1. Expect quarterly losses to keep rising through 2027. Higher interest income on the larger cash pile will offset only a small part of that.

The main uncertainty is scientific, not financial. IL-31 is a known itch target, and a single positive Phase 1b that is still preliminary does not establish that ATTO-1310 will beat existing treatments in the larger, placebo-controlled Phase 2 studies. What to watch next: (1) the full Phase 1b data in Q4 2026, in particular how large the itch reduction is against placebo and how long one dose lasts; (2) whether the CPUO Phase 2 protocol, already submitted to the FDA, starts on schedule in the first half of 2027; (3) quarterly operating cash burn against the roughly $30 million per quarter that the 2030 runway implies.